Michael H Tomasson
Overview
Explore the profile of Michael H Tomasson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
9995
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Vasilyev M, Berschel M, Tomasson M, Bates M
Exp Physiol
. 2021 Mar;
106(6):1315-1316.
PMID: 33728739
No abstract available.
12.
Oliveira V, Mahajan N, Bates M, Tripathi C, Kim K, Zaher H, et al.
FASEB Bioadv
. 2020 Feb;
1(7):404-414.
PMID: 32095781
The orphan small nucleolar RNA (snoRNA) ACA11 is overexpressed as a result of the t(4;14) chromosomal translocation in multiple myeloma (MM), increases reactive oxygen species, and drives cell proliferation. Like...
13.
Sun F, Cheng Y, Walsh S, Acevedo M, Jing X, Han S, et al.
Haematologica
. 2019 Jun;
105(3):e111-e115.
PMID: 31221780
No abstract available.
14.
Ali M, Kowkuntla S, Delloro D, Galambos C, Hathi D, Janz S, et al.
Am J Physiol Regul Integr Comp Physiol
. 2019 Mar;
316(5):R678-R686.
PMID: 30892915
Obesity is the only known modifiable risk factor for multiple myeloma (MM), an incurable cancer of bone marrow plasma cells. The mechanism linking the two is unknown. Obesity is associated...
15.
Glenn M, Madsen M, Davis E, Garner C, Curtin K, Jones B, et al.
Blood Cancer J
. 2019 Feb;
9(3):25.
PMID: 30808891
Abnormal serum immunoglobulin (Ig) free light chains (FLC) are established biomarkers of early disease in multiple B-cell lymphoid malignancies, including chronic lymphocytic leukemia (CLL). Heavy chains have also been shown...
16.
Altrock P, Ferlic J, Galla T, Tomasson M, Michor F
JCO Clin Cancer Inform
. 2019 Jan;
2:1-12.
PMID: 30652561
Purpose: Recent advances have uncovered therapeutic interventions that might reduce the risk of progression of premalignant diagnoses, such as monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM). It...
17.
Tomasson M, Ali M, de Oliveira V, Xiao Q, Jethava Y, Zhan F, et al.
Int J Mol Sci
. 2018 Nov;
19(11).
PMID: 30453544
Multiple myeloma is an invariably fatal cancer of plasma cells. Despite tremendous advances in treatment, this malignancy remains incurable in most individuals. We postulate that strategies aimed at prevention have...
18.
White B, Lanc I, ONeal J, Gupta H, Fulton R, Schmidt H, et al.
Blood Cancer J
. 2018 Mar;
8(3):35.
PMID: 29563506
Multiple myeloma (MM) is a disease of copy number variants (CNVs), chromosomal translocations, and single-nucleotide variants (SNVs). To enable integrative studies across these diverse mutation types, we developed a capture-based...
19.
Mahajan N, Wu H, Bennett R, Troche C, Licht J, Weber J, et al.
FASEB J
. 2017 Feb;
31(2):482-490.
PMID: 28148777
Overexpression of the multiple myeloma set domain (MMSET) Wolf-Hirschhorn syndrome candidate 1 gene, which contains an orphan box H/ACA class small nucleolar RNA, ACA11, in an intron, is associated with...
20.
Welch J, Petti A, Miller C, Fronick C, OLaughlin M, Fulton R, et al.
N Engl J Med
. 2016 Dec;
375(21):2023-2036.
PMID: 27959731
Background: The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear. Methods: We enrolled 84 adult patients with...